Slide 1: Q1 2021 Results
We engineer enzymes to improve health… of people and the planet Q1 2021 Results May 6, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and
Slide 3: Growth Drivers Continue to Accelerate
Growth Drivers Continue to Accelerate Strong Q1’21 Results Executing on Growth Opportunities Total revenue growth of 23% Sustainable Manufacturing: Exciting late clinical stage enzyme installations adding to solid commercial products base Quarterly Product Revenue Doubled YOY Life Sciences: Accelera
Slide 4: Sustainable Manufacturing: Solid, Growing Base with Expanding Margins
Sustainable Manufacturing: Solid, Growing Base with Expanding Margins % Total 2020 Performance Enzymes Revenue Islatravir, antiviral drug candidate Sustainable Manufacturing - • Converted 16-step process into 3-step process Food & Industrial 4% • Higher yield and capital efficiency for Merck • >$1M
Slide 5: Life Science Tools: High Growth
Life Science Tools: High Growth Codex® HiCap RNA polymerase Strong Progress in Q1’21 • Significantly higher capping efficiency w/much lower 5’ cap concentration • Initial sales of Codex® HiCap RNA polymerase • Decreased unwanted double-stranded RNA synthesis to multiple customers; under testing with
Slide 6: Biotherapeutics: Rapid Pipeline Expansion and Validation
Biotherapeutics: Rapid Pipeline Expansion and Validation Preclinical Clinical # of Program Discovery Research IND Enabling Phase I Partnership to discover optimized transgenes for Takeda’s gene therapies for Fabry and Pompe Diseases, plus an undisclosed blood factor deficiency 2016 1 1 Advancing Lea
Slide 7: Strong Q1 2021 Results
Strong Q1 2021 Results $18M $10M 59% Q1’21 Total Q1’21 Product Gross Product Margin Revenue +23% Revenue +100% vs. 50% in Q1’20 $140M $14M $4M Cash Available for Growth. No Debt Performance Novel Enzymes Biotherapeutics $12M $11M $(9)M R&D Expense SG&A Expense Net Loss 7
Slide 8: Reiterating 2021 Guidance
Reiterating 2021 Guidance $82-85M $36-39M 54-58% Total Revenue Product Revenue Product Gross Margin
Slide 9: Executing 2021 Corporate Goals and Catalysts
Executing 2021 Corporate Goals and Catalysts q Enzymes for Phase 2 / 3 pharma processes commercialize into new recurring product revenues Sustainable q Continue widening pharma adoption and advancing clients to new CodeEvolver® platform deals Manufacturing q $M+ food enzymes revenues from Tate & Lyl
Slide 10: We engineer enzymes to improve health… of people and the planet
We engineer enzymes to improve health… of people and the planet Nasdaq: CDXS www.codexis.com